quinazolines has been researched along with Endometrial Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Annunziata, CM; Cao, L; Cimino-Mathews, A; Figg, WD; Gatti-Mays, M; Houston, ND; Kohn, EC; Lee, JM; Lee, MJ; Lipkowitz, S; Mikkilineni, L; Nichols, E; Peer, C; Sharma, R; Trepel, JB; Zimmer, AS | 1 |
| Baron, AT; Darcy, KM; Fischer, E; Godwin, AK; Hanjani, P; Leslie, KK; Maihle, NJ; Mannel, RS; Schilder, RJ; Sill, MW; Singh, M; Tewari, KS; Wilken, JA | 1 |
| Cho-Clark, M; Larco, DO; Mani, SK; Semsarzadeh, NN; Vasta, F; Wu, TJ | 1 |
| Chang, TC; Chao, A; Chao, AS; Chou, HH; Hsueh, S; Huang, HJ; Lai, CH; Lee, YS; Lin, CY; Wang, TH; Wu, TI | 1 |
| Muggia, F; Teplinsky, E | 1 |
| Azodi, M; Bellone, S; Bonazzoli, E; Bortolomai, I; Cocco, E; English, DP; Lopez, S; Nicoletti, R; Ratner, E; Roque, DM; Rutherford, TJ; Santin, AD; Schwab, CL; Schwartz, PE; Silasi, DA | 1 |
| Bender, D; Darus, CJ; Delmore, JE; Gray, HJ; Hunter, MI; Lankes, HA; Leslie, KK; Mannel, RS; McCourt, CK; Reyes, HD; Rotmensch, J; Samuelson, MI; Schilder, JM; Sill, MW | 1 |
| Peng, Z; Shi, H; Wang, J; Xie, Y | 1 |
| Lang, B; Meng, LR; Shang, C | 1 |
| Abbadessa, G; Eathiraj, S; Hall, T; Schwartz, B; Wick, MJ; Yu, Y | 1 |
| Biagi, J; Cutz, JC; Dancey, J; Dore, N; Eisenhauer, EA; Elit, L; Fyles, A; Ghatage, P; Hoskins, PJ; Mazurka, J; Oza, AM; Provencher, D; Sakurada, A; Tsao, MS | 1 |
| Brown, J; Gaikwad, A; Ramondetta, LM; Smith, JA; Wolf, JK | 1 |
| Ai, Z; Teng, Y; Tong, J; Wang, J; Xu, Y | 1 |
| Abulafia, O; Fischer, EG; Godwin, AK; Gray, H; Hanjani, P; Lankes, HA; Leslie, KK; Rose, PG; Schilder, RJ; Sill, MW; Tewari, K; Walker, JL | 1 |
| Ai, Z; Teng, Y; Wang, J; Xu, Y; Yan, Y | 1 |
| Albitar, L; Brachova, P; Dai, D; Ianzini, F; Kosmacek, EA; Laidler, LL; Leslie, KK; Liu, D; Mackey, MA; Meng, X; Wang, X; Xiong, Z; Yang, S; Zhang, Y; Zhu, D | 1 |
| Abdallah, R; Albitar, L; Laidler, LL; Leslie, KK | 1 |
| Albitar, L; Carter, MB; Davies, S; Leslie, KK | 1 |
| Dering, J; Fejzo, MS; Finn, R; Ginther, C; Jiang, SW; Konecny, GE; Podratz, KC; Rahmeh, M; Slamon, DJ; Toft, D; Venkatesan, N; Yang, G | 1 |
1 review(s) available for quinazolines and Endometrial Neoplasms
| Article | Year |
|---|---|
Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Topics: Adenocarcinoma, Mucinous; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Ovarian Neoplasms; Quinazolines; Trastuzumab; Uterine Neoplasms | 2014 |
5 trial(s) available for quinazolines and Endometrial Neoplasms
| Article | Year |
|---|---|
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Quinazolines; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Survival Rate | 2013 |
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines | 2015 |
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Endometrial Neoplasms; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2008 |
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; DNA Mutational Analysis; Drug Administration Schedule; Endometrial Neoplasms; Female; Genes, erbB-1; Genetic Markers; Humans; Immunohistochemistry; Lapatinib; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
13 other study(ies) available for quinazolines and Endometrial Neoplasms
| Article | Year |
|---|---|
GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor.
Topics: Calcium Signaling; Cell Line, Tumor; Cell Movement; Endometrial Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression; Gonadotropin-Releasing Hormone; Humans; Matrix Metalloproteinase Inhibitors; Oligopeptides; Oncogene Proteins; Peptide Fragments; Phenylalanine; Phosphorylation; Protein Processing, Post-Translational; Pyrrolidonecarboxylic Acid; Quinazolines; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Receptors, LHRH; Thiophenes; Transcriptional Activation; Tyrphostins | 2014 |
A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Endometrial Neoplasms; Endometrium; ErbB Receptors; Female; Humans; Lapatinib; MAP Kinase Signaling System; Matrix Metalloproteinase 1; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factor AP-1; Up-Regulation | 2014 |
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; In Vitro Techniques; Mice; Mice, SCID; Middle Aged; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
[Research of the influence and mechanism about metformin on the proliferation of differentiated endometrial carcinoma cells].
Topics: Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Down-Regulation; Endometrial Neoplasms; Endometrium; Female; Humans; Hypoglycemic Agents; Metformin; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Signal Transduction; Tyrphostins | 2015 |
Blocking NOTCH pathway can enhance the effect of EGFR inhibitor through targeting CD133+ endometrial cancer cells.
Topics: AC133 Antigen; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Diamines; Drug Resistance, Neoplasm; Drug Synergism; Endometrial Neoplasms; ErbB Receptors; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Receptors, Notch; Signal Transduction; Thiazoles; Tyrphostins; Xenograft Model Antitumor Assays | 2018 |
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Topics: Aminopyridines; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Fibroblast Growth Factor; Xenograft Model Antitumor Assays | 2017 |
In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Phosphorylation; Quinazolines; Receptors, Progesterone; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Influence of epidermal growth factor receptor inhibitor AG1478 on epithelial-mesenchymal transition in endometrial carcinoma cells.
Topics: Carcinoma; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endometrial Neoplasms; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Quinazolines; Tumor Cells, Cultured; Tyrphostins | 2012 |
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Endometrial Neoplasms; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Mitosis; Paclitaxel; Pteridines; Quinazolines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Endometrial Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Phosphoproteins; Quinazolines; Signal Transduction | 2005 |
Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.
Topics: Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gefitinib; Genes, Tumor Suppressor; Humans; PTEN Phosphohydrolase; Quinazolines; Retinoblastoma Protein; Transfection; Tumor Suppressor Protein p53 | 2007 |
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Screening Assays, Antitumor; Endometrial Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lapatinib; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2008 |